Clinical Trials
46
Trial Phases
3 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Conditions
- Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer
- Interventions
- Drug: DCC-2812
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06966024
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06630234
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619561
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
- Conditions
- Advanced Solid TumorRAF MutationRAS MutationNF1 MutationNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaMelanomaBRAF Gene MutationCRAF Gene MutationCastration-Resistant Prostate Cancer (CRPC)
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT06287463
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05957367
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- Next